Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCIDITY: TRx0237 Monotherapy in Alzheimer's Disease
NCT03446001Phase 3Completed
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Dec 2017
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of hydromethylthionine mesylate in Alzheimer's disease (AD), sponsored by TauRx Therapeutics Ltd. Started Dec 2017; status: completed.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03446001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446001.